Current UV Index
UV index: 0.0
Alice Springs
UV index: 0.0
UV index: 0.0
UV index: 0.0
UV index: 0.0
UV index: 0.0
Gold Coast
UV index: 0.0
UV index: 0.0
UV index: 0.0
UV index: 0.0
UV index: 0.0
UV index: 0.0
UV index: 0.0

Click the indexes to view the minimum recommended protection

When the UV index is low, sun protection is generally not needed unless outside for extended periods

UV observations courtesy of ARPANSA

Fast facts

  • Around 36 Australians are diagnosed with Melanoma every day.
  • Australia has one of the highest rates of Melanoma in the world.
  • Approx one person dies every 5 hours from Melanoma in Australia.
  • An estimated 545 Australian women will die from melanoma THIS YEAR.
  • Tanning beds emit dangerous UV rays, increasing the risk of Melanoma.
  • Severe sunburn during childhood can DOUBLE your risk of Melanoma.
  • Melanoma is one of the most preventable forms of cancer.
  • An estimated 1230 Australian men will die from melanoma THIS YEAR.
  • Melanoma is the cancer most likely to affect 15-39 year olds.
  • Melanoma can arise in normal looking skin, a mole or freckle.
  • Melanoma, if detected/treated early, has a survival rate of nearly 100%.
  • There is no cure for melanoma that has spread throughout the body.


Our Focus

The AMRF is committed to funding research aimed at furthering knowledge and offering better outcomes in the prevention, diagnosis and treatment of melanoma.

Our aim is to support research that leads to a reduction in the incidence of melanoma and its impact on those living with the cancer.

The AMRF will focus on supporting early career researchers in Australia.

The Foundation has established an evaluation framework to assist in the identification of the key research areas to optimise our funding support.

Over the past few years the AMRF has provided funding to support research that has had a positive impact for some with melanoma.

Current Research Projects being funded:

Introducing Dr Pablo Garcia Valtanen supervisor for Ms Samantha Watson, a PhD student at University of South Australia (UniSA), who is investigating the potential for treating melanoma with a medicine that has successfully targeted oesophageal cancer cells in the laboratory. Although different, certain cancerous cells in the oesophagus and in melanoma share common traits such as the expression of disease specific molecules on their surface. One of these molecules, is the focus of Ms Watson’s project which is trying to find new ways for treating melanoma.  Her goal is to establish the potential for the use of antibodies in the clinic.  This strategy has already generated positive results with oesophageal cancer models and Ms Watson now expects to replicate this success in melanoma cells.

Funding from the AMRF is supporting this vital Research.

Meet The Team:

  • Ms Samantha J Watson: Currently an Honours degree student at the Experimental Therapeutics Laboratory (ETL) and PhD candidate from next year. The work funded by the AMRF will be integrated as part of Samantha’s thesis project to conduct laboratory tests towards a new treatment method to complement existing chemotherapy drugs.
  • Mr Antony Scammell: Founder and Director of ConCa Pty Ltd. Mr Scammell has funded, supervised and worked for many years to bring the ConCa project to its current state where candidate antibodies against the human EPHB4 receptor have been developed to successfully attack cancer cells.
  • Ms Jamie Zhang: An experienced Research Officer who has worked on all aspects of the ConCa project for the last 3 years and contributed enormously to the success of the project.
  • Professor John D Hayball: Head of the Experimental Therapeutics Laboratory and professor at University of South Australia supervises different projects that link industry and academia to bring therapeutic candidates closer to the clinic and treat cancer as well as infectious diseases.
  • Dr Pablo Garcia Valtanen: Postdoctoral scientist managing and supervising the ConCa project for the last 2 years. Dr Garcia Valtanen will directly supervise and contribute to Samantha’s work funded by AMRF.

Dr Pablo Garcia Valtanen and Ms Samantha J Watson. Photo by Emma Brasier.

Previously funded research projects include:

Improving Melanoma Therapy Using Timed Coordinated Vaccine & Chemotherapy Delivery: Timed vs Untimed VMCL Melanoma Vaccine Therapy Phase III Study for Patients with Advanced Stage IV Melanoma: Chief Investigator Prof Brendon Coventry, University of Adelaide.

- Analysis of the completed EMOTIV (“Enhancing Melanoma Outcomes using a Timed Immunotherapy Vaccine”) Melanoma Vaccine Study

- Analysis of the cyclical behaviours of the human immune system as it effects vaccine therapies

- Analysis of the long-term survival outcomes in the VMCL (“Vaccinia Melanoma Cell Lysate”) Trial

- The effect of timing on the IL-2 (“Interleukin-2 Melanoma Therapy”)